MedImpact Holdings, Inc. has introduced a new unbranded version of the blockbuster drug Humira adalimumab, priced at 95 percent less than the reference product. The biosimilar, Adalimumab-ryvk, is being manufactured by Anda, an affiliate of Teva Pharmaceuticals USA, Inc., and will be distributed through MedImpact’s preferred partner, Birdi Inc. Unlike many industry programs that limit availability to affiliated networks, this product will be accessible to hospitals, health plans, and licensed pharmacies across the United States, regardless of whether they are existing MedImpact clients.
Health Technology Insights: Hikma Launches EXOMIND, FDA-Cleared Drug-Free Depression Therapy
The company says the move reflects a broader effort to address longstanding pricing challenges in the pharmaceutical supply chain. Zach Johnson, Executive Vice President at MedImpact, stated that the traditional system has often relied on complex distribution structures that make it difficult to understand the true cost of medications. He explained that this launch represents a shift toward a model focused on transparency, affordability, and improved patient access rather than incremental pricing adjustments.
This marks the second interchangeable biosimilar introduced by MedImpact within six months as part of its strategy to reduce specialty drug spending. Humira remains one of the most widely prescribed biologic therapies in the country, and the availability of a significantly lower priced alternative could meaningfully reduce costs for employers, plan sponsors, and public programs while expanding access for patients who depend on the therapy.
Health Technology Insights: Rx Assistant Launches AI Hub for Medication Access and Adherence
MedImpact’s approach differs from common pharmacy benefit manager practices in several ways. The company is offering open market access so that savings are not confined to specific in house or affiliated pharmacies. The 95 percent price reduction is positioned as one of the most aggressive discounts currently available among Humira biosimilars. In addition, the product has received an interchangeable designation from the US Food and Drug Administration, allowing pharmacists to substitute it where permitted, which may help accelerate adoption. The company has also developed prescriber and patient support initiatives intended to increase confidence in biosimilars and address barriers that have slowed uptake in the past.
Another distinguishing feature of the program is its pricing structure. MedImpact is not relying on retrospective rebates or complex incentive arrangements. Instead, the discount is applied directly at the point of purchase, providing upfront savings and greater visibility into actual drug costs. This structure is designed to give plan sponsors clearer financial control and reduce uncertainty around net pricing.
Arpit Patel, PharmD, Senior Vice President of Trade Relations and Supply Chain at MedImpact, said the organization continues to evaluate additional biosimilar opportunities that meet its clinical and financial standards. He noted that future launches will follow the same principles of transparency, cost savings, and patient centered access. According to Patel, the company’s goal is to provide clients with straightforward options that deliver measurable savings while ensuring members receive appropriate and affordable treatment.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 4 February 2026
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
